Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Lowered by Wall Street Zen

Posted by Stanley Muller on Oct 31st, 2026

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

KYMR has been the topic of several other reports. Mizuho boosted their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Royal Bank Of Canada increased their price target on Kymera Therapeutics from $112.00 to $116.00 and gave the company a “sector perform” rating in a report on Friday. Barclays increased their price target on Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. BTIG Research lifted their price objective on Kymera Therapeutics from $134.00 to $139.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective on the stock in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $137.92.

Check Out Our Latest Stock Analysis on KYMR

Kymera Therapeutics Trading Up 3.3%

KYMR stock opened at $126.63 on Friday. Kymera Therapeutics has a 12-month low of $55.66 and a 12-month high of $130.05. The business’s 50-day moving average is $114.93 and its 200 day moving average is $96.35. The stock has a market cap of $10.53 billion, a price-to-earnings ratio of -34.98 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). The firm had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.65%. Kymera Therapeutics’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.94) EPS. As a group, equities analysts forecast that Kymera Therapeutics will post -3.85 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Brian Adams sold 6,371 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kymera Therapeutics during the third quarter worth approximately $514,000. China Universal Asset Management Co. Ltd. boosted its holdings in Kymera Therapeutics by 20.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock valued at $1,747,000 after purchasing an additional 2,721 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in Kymera Therapeutics by 378.6% in the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock valued at $215,000 after purchasing an additional 1,518 shares in the last quarter. Inspire Investing LLC acquired a new position in Kymera Therapeutics in the third quarter valued at approximately $482,000. Finally, Nisa Investment Advisors LLC increased its stake in Kymera Therapeutics by 45.9% in the third quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock valued at $232,000 after purchasing an additional 652 shares during the last quarter.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.